[
  {
    "ts": null,
    "headline": "Cardinal Health Inc. stock underperforms Monday when compared to competitors",
    "summary": "Cardinal Health Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=36ef4c28a39d8b6d90d44c1ebd8408c131a75f1b2a0fe011be6e199a834fc17e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733763780,
      "headline": "Cardinal Health Inc. stock underperforms Monday when compared to competitors",
      "id": 131886753,
      "image": "",
      "related": "CAH",
      "source": "MarketWatch",
      "summary": "Cardinal Health Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=36ef4c28a39d8b6d90d44c1ebd8408c131a75f1b2a0fe011be6e199a834fc17e"
    }
  },
  {
    "ts": null,
    "headline": "T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens",
    "summary": "Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue streamLEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to license its proprietary technology to expand its leadership in direct-from-whole-blood detection of sepsis-causing pathogens. T2 Bi",
    "url": "https://finnhub.io/api/news?id=635f5f7730b2e1fce3f4fbde3e46038a52d0ffa65b8b4d1f4968df7406efa136",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733752800,
      "headline": "T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens",
      "id": 131896531,
      "image": "https://media.zenfs.com/en/globenewswire.com/76ea202e662dd8e06f1c612524529829",
      "related": "CAH",
      "source": "Yahoo",
      "summary": "Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue streamLEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to license its proprietary technology to expand its leadership in direct-from-whole-blood detection of sepsis-causing pathogens. T2 Bi",
      "url": "https://finnhub.io/api/news?id=635f5f7730b2e1fce3f4fbde3e46038a52d0ffa65b8b4d1f4968df7406efa136"
    }
  },
  {
    "ts": null,
    "headline": "Cardinal Health : Material Agreement Form 8 K",
    "summary": "Item 1.01. Entry into a Material Definitive Agreement On December 5, 2024, Cardinal Health, Inc. , Bank of America, N.A., as Administrative Agent and each lender from time to time...",
    "url": "https://finnhub.io/api/news?id=e7a2fb8962c7f08a087d394cb512ce3390a5f3df45380b57bcf0e291ee100ae9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733725564,
      "headline": "Cardinal Health : Material Agreement Form 8 K",
      "id": 131867501,
      "image": "",
      "related": "CAH",
      "source": "Finnhub",
      "summary": "Item 1.01. Entry into a Material Definitive Agreement On December 5, 2024, Cardinal Health, Inc. , Bank of America, N.A., as Administrative Agent and each lender from time to time...",
      "url": "https://finnhub.io/api/news?id=e7a2fb8962c7f08a087d394cb512ce3390a5f3df45380b57bcf0e291ee100ae9"
    }
  }
]